Clinical Trial Update: A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing different dosing regimens of ixekizumab (LY2439821) in adults with moderate to severe plaque psoriasis has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-04-18